The influence of propofol on P-selectin expression and nitric oxide production in re-oxygenated human umbilical vein endothelial cells.
BACKGROUND
Reperfusion injury is characterized by free radical production and endothelial inflammation. Neutrophils mediate much of the end-organ injury that occurs, requiring P-selectin-mediated neutrophil-endothelial adhesion, and this is associated with decreased endothelial nitric oxide production. Propofol has antioxidant properties in vitro which might abrogate this inflammation.


METHODS
Cultured human umbilical vein endothelial cells were exposed to 20 h of hypoxia and then returned to normoxic conditions. Cells were treated with saline, Diprivan 5 microg/l or propofol 5 microg/l for 4 h after re-oxygenation and were then examined for P-selectin expression and supernatant nitric oxide concentrations for 24 h. P-selectin was determined by flow cytometry, and culture supernatant nitric oxide was measured as nitrite.


RESULTS
In saline-treated cells, a biphasic increase in P-selectin expression was demonstrated at 30 min (P = 0.01) and 4 h (P = 0.023) after re-oxygenation. Propofol and Diprivan prevented these increases in P-selectin expression (P < 0.05). Four hours after re-oxygenation, propofol decreased endothelial nitric oxide production (P = 0.035).


CONCLUSIONS
This is the first study to demonstrate an effect of propofol upon endothelial P-selectin expression. Such an effect may be important in situations of reperfusion injury such as cardiac transplantation and coronary artery bypass surgery. We conclude that propofol attenuates re-oxygenation-induced endothelial inflammation in vitro.
Corcoran
T B
TB
Department of Anaesthesia, Cork University Hospital, Cork City, Republic of Ireland. mascor@gofree.indigo.ie
O'Shea
A
A
Engel
A
A
Shorten
G D
GD
D000975:Antioxidants / Q000494:pharmacology; D015687:Cell Hypoxia; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D009569:Nitric Oxide / Q000096:biosynthesis*; D052250:Nitric Oxide Synthase Type III / Q000032:analysis; D010100:Oxygen / Q000494:pharmacology*; D019007:P-Selectin / Q000032:analysis*; D015742:Propofol / Q000494:pharmacology*; D015427:Reperfusion Injury / Q000517:prevention & control
D000975:Antioxidants; D019007:P-Selectin; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III; D010100:Oxygen; D015742:Propofol